https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-6602021-07-20 00:00:002023-03-14 09:44:20Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-19 / Sci Rep 2021 Jul;11(1):14661
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-19 / Sci Rep 2021 Jul;11(1):146612021-07-19 00:00:002021-07-19 00:00:00Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-04 / Cancer Immunol Immunother 2021 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-3427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-34272021-07-01 00:00:002023-03-07 11:15:55Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-19862021-06-29 00:00:002021-06-29 00:00:00A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-28 / Front Cell Dev Biol 2021;9:686544
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-28 / Front Cell Dev Biol 2021;9:6865442021-06-28 00:00:002021-06-28 00:00:00Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-58402021-06-18 00:00:002023-01-31 13:08:35Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-17342021-06-17 00:00:002023-01-31 13:09:00Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)2021-06-09 00:00:002021-06-09 00:00:00Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)2021-06-04 00:00:002021-06-04 00:00:00Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
